Observational Study of Gut Microbiome and Cancer-Related Symptoms
This study is looking at how the gut microbiome (the community of bacteria and other tiny organisms in your intestines) might be connected to cancer-related fatigue and cognitive impairment (CRCI), which is a decrease in thinking abilities. Researchers will collect information from 250 people with cancer to understand the makeup of their gut microbiome. They will also assess fatigue and thinking abilities. The goal is to see if there are common patterns in the gut microbiome that are linked to these symptoms across different types of cancer and treatments. You can join if you are 18 or older, have a cancer diagnosis, and have internet access. This is an observational study, meaning you won't receive any new treatments.
- Study design
- This is an observational study planning to enroll 250 participants. It is not a treatment study, but rather aims to collect information.
- What's involved
- Participants will provide fecal samples at the beginning of the study and again at 6 months. They will also be assessed for fatigue and cognitive impairment.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 6 months after the initial assessment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Correlates of CRCI and Gut Microbiome Dysbiosis; a Pilot Study
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Melinda Sheffield-Moore, PhD · PRINCIPAL_INVESTIGATOR · University of Texas
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Characterization of fecal microbiome using molecular methods at baselineBaseline
Characterization of the fecal microbiome using a commercially available sampling kit and our lab's patented array for PCR at baseline
- Characterization of fecal microbiome using molecular methods at 6 months6 months
Characterization of the fecal microbiome using a commercially available sampling kit and our lab's patented array for PCR after 6 months of standard of care treatment.